TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27129006
Drug: Darunavir oral
Normalized name: darunavir Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darunavir oral suspension (100 mg/mL, 6 mL) with low-dose ritonavir (100 mg, days 1-5)
Study: 27129006
Drug: Darunavir tablets
Normalized name: Darunavir Tablets
DrugBank: Darunavir (DB01264)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Darunavir tablets (600 mg, 2 x 300 mg) with low-dose ritonavir (100 mg, days 1-5)
Study: 27129006
Drug: Darunavir oral
Normalized name: darunavir Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darunavir oral suspension (600 mg) with low-dose ritonavir (100 mg, days 1-9)
Study: 20041911
Drug: Ocinaplon 90
Normalized name: Ocinaplon
DrugBank: Ocinaplon (DB06529)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ocinaplon 90 mg t.i.d.
Study: 17670917
Drug: Lifestyle modification
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifestyle modification and metformin
Study: 15732092
Drug: BILN‐2061, 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: BILN‐2061, 500 mg twice-daily for 2 days
Study: 11874817
Drug: Nebulized budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nebulized budesonide (2 mg every 6 h, n = 71)
Study: 11874817
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (30 mg every 12 h, n = 62)
Study: 8860064
Drug: Nisoldipine 20
Normalized name: nisoldipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nisoldipine 20 mg once daily
Study: 8522634
Drug: Nisoldipine 60
Normalized name: Nisoldipine
DrugBank: Nisoldipine (DB00401)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nisoldipine 60 mg once daily
Study: 8522634
Drug: Nisoldipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nisoldipine (20 mg and 60 mg)
Study: 31444972
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy ± bevacizumab
Study: 20568428
Drug: Three-step acupuncture
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-step acupuncture combined with oral administration of Aspirin for six months
Study: 20568428
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of Aspirin alone
Study: 20568428
Drug: Three-step acupuncture
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-step acupuncture combined with oral administration of Aspirin
Study: 14664898
Drug: Simvastatin 80
Normalized name: simvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 80 mg/day (n=16)
Study: 14664898
Drug: Atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40 mg/day (n=16)
Study: 29917215
Drug: Micronised dispersible
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronised dispersible ferric pyrophosphate plus alpha-lactalbumin (MDFP-AL), 30 mg of MDFP-AL per day for 30 days
Study: 29917215
Drug: Ferrous gluconate
Normalized name: Ferrous Gluconate
DrugBank: Ferrous gluconate (DB14488)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous gluconate (FG), 80 mg of FG per day for 30 days
Study: 27889710
Drug: IV maintenance
Normalized name: ReddyPort NIV Maintenance Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV maintenance therapy with phenobarbitone
Study: 18794651
Drug: Antipsychotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic treatment (specifics not provided)
Study: 1531464
Drug: Intranasal nafarelin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal nafarelin 200 micrograms two times a day
Study: 1531464
Drug: Oral danazol
Normalized name: Danazol
DrugBank: Danazol (DB01406)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral danazol 200 mg three times a day
Study: 24915052
Drug: Nifedipine GITS
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine GITS 30 mg plus Valsartan 80 mg (N30+V80)
Study: 24915052
Drug: Nifedipine GITS
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine GITS 60 mg (N60)
Study: 15579516
Drug: Valsartan 160
Normalized name: valsartan 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 160 mg (V160)
Study: 22168345
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of alcohol per kilogram of body mass
Study: 20224514
Drug: Concentration-controlled mycophenolate
Normalized name: mycophenolate
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concentration-controlled mycophenolate mofetil (MMF) dosing based on mycophenolic acid (MPA) exposure
Study: 20224514
Drug: Concentration-controlled mycophenolate
Normalized name: mycophenolate
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concentration-controlled mycophenolate mofetil (MMF) dosing
Study: 20224514
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (Concentration-controlled and Fixed-dose)
Study: 1433451
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine alone (3 doses at 0, 1, 2 months)
Study: 1433451
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine + HBIG (3 doses at 0, 1, 2 months)
Study: 6228473
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine alone
Study: 1433451
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine + HBIG
Study: 28370973
Drug: 7 days
Normalized name: ZINGIBER OFFICINALE (GINGER) ROOT OIL 0.006 mg in 30 mg TOPICAL LIQUID [JAYSUING 7 Days Nail Fungus Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 days of antibiotic treatment according to bacteriogram sensitivity
Study: 28370973
Drug: Observational group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observational group (no treatment)
Study: 27185197
Drug: Ofatumumab 1000
Normalized name: ofatumumab 1000 MG in 50 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofatumumab 1000 mg on days 1 and 8 of the first cycle and day 1 of the second and third cycles (O-ESHAP)
Study: 24645632
Drug: Non-skin cancers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-skin cancers (oral, lung, colon, breast, prostate, thyroid, leukemia, lymphoma, central nervous system)
Study: 3219315
Drug: Meals containing
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meals containing 220 g protein/kg dry weight
Study: 23552127
Drug: Zofenopril 60
Normalized name: Zofenopril
DrugBank: Zofenopril (DB13166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zofenopril 60 mg and ASA 100 mg
Study: 23552127
Drug: Ramipril 10
Normalized name: ramipril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril 10 mg and ASA
Study: 16450089
Drug: N-acetylcysteine (1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine (1,200 mg)
Study: 8930154
Drug: Naltrexone (3.125,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (3.125, 12.5, 50 and 200 mg)
Study: 8930154
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of cocaine and hydromorphone
Study: 27311415
Drug: 2000 mg
Normalized name: bran 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000 mg calcium supplementation
Study: 27311415
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg calcium supplementation
Study: 22855866
Drug: Caffeine 100
Normalized name: caffeine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 100 mg twice daily for 3 weeks, then 200 mg twice daily for 3 weeks
Study: 20727160
Drug: Wood smoke
Normalized name: Wood creosote
DrugBank: Wood creosote (DB13271)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wood smoke exposure (PM2.5 concentration of 224 ± 22 μg/m3)
Study: 12818631
Drug: s.c. melagatran
Approvals — FDA: no, EMA: no, PMDA: no
Description: s.c. melagatran (1-3 mg bid) followed by oral ximelagatran (8-24 mg bid)
Study: 12818631
Drug: s.c. melagatran
Approvals — FDA: no, EMA: no, PMDA: no
Description: s.c. melagatran (3 mg bid) followed by oral ximelagatran (24 mg)
Study: 12818631
Drug: s.c. enoxaparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: s.c. enoxaparin (40 mg od)
Study: 10353130
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (control group with 9 patients).
Study: 1773905
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of bacterial extracts over 16 weeks
Study: 1773905
Drug: Intramuscular benzanthine
Normalized name: Cephapirin Benzathine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular benzanthine penicillin
Study: 6258375
Drug: pancuronium 0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: pancuronium 0.01 mg/kg
Study: 9424681
Drug: pancuronium 0.015
Approvals — FDA: no, EMA: no, PMDA: no
Description: pancuronium 0.015 mg/kg
Study: 6258375
Drug: gallamine 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: gallamine 0.3 mg/kg
Study: 6258375
Drug: gallamine 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: gallamine 0.4 mg/kg
Study: 24518370
Drug: 1600 μg
Normalized name: hyaluronidase
DrugBank: Hyaluronidase (DB14740)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1600 μg of salbutamol
Study: 21046356
Drug: Rapamycin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapamycin monotherapy (0.1 mg/kg; target trough levels 8-10 ng/ml; 26-314 days)
Study: 21046356
Drug: Rapamycin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapamycin monotherapy
Study: 18506181
Drug: Erlotinib at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib at 50 mg (cohort 1), 100 mg (cohort 2a), or 75 mg (cohort 2b) day(‐1) for up to six cycles with docetaxel (75 mg m(‐2)) and carboplatin (AUC 5) on day 1 of a 3-week cycle.
Study: 18506181
Drug: Single-agent maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-agent maintenance erlotinib at 100-150 mg day(‐1) after initial treatment.
Study: 10928428
Drug: Crinone 8%
Normalized name: Crinone 8% Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crinone 8% (90 mg progesterone vaginal gel) twice daily
Study: 10928428
Drug: Crinone 8%
Normalized name: Crinone 8% Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crinone 8% (90 mg progesterone vaginal gel) once daily
Study: 10928428
Drug: i.m. progesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.m. progesterone (100 mg)
Study: 10928428
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment groups (Crinone and i.m. progesterone)
Study: 1345029
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of ioxaglate
Study: 1345029
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of iopamidol
Study: 6205060
Drug: Mezlocillin 2
Normalized name: mezlocillin 250 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mezlocillin 2 g
Study: 28258928
Drug: Inhaled mannitol
Normalized name: mannitol Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled mannitol 400mg every 12h for 8 weeks
Study: 26237001
Drug: Ropivacaine 0.1%
Normalized name: ROPivacaine 0.1% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.1% 10 mL
Study: 26237001
Drug: Ropivacaine 0.1%
Normalized name: ROPivacaine 0.1% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.1% 30 mL
Study: 21943294
Drug: Web-based self-help
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based self-help therapy (6-week duration, based on Cognitive Behavioural Therapy, Motivational Interviewing, and self-control practices)
Study: 21943294
Drug: Web-based self-help
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based self-help therapy
Study: 21943294
Drug: Weekly psycho-educative
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly psycho-educative information with a quiz (control group)
Study: 16582527
Drug: Phase I
Normalized name: Nuvelle TS Phase I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase I periodontal treatment including scaling, root planning, and 0.2% chlorhexidine mouth rinse for one week
Study: 16582527
Drug: Phase I
Normalized name: Nuvelle TS Phase I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase I periodontal treatment
Study: 8736653
Drug: terbutaline Turbuhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: terbutaline Turbuhaler (0.5 mg t.i.d.)
Study: 8736653
Drug: salbutamol Rotahaler
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: salbutamol Rotahaler (0.4 mg t.i.d.)
Study: 1434838
Drug: TAD (for
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAD (for induction and consolidation) followed by monthly myelosuppressive maintenance for 3 years; second induction course either TAD or HAM for patients less than 60 years.
Study: 24558403
Drug: recombinant Canarypox
Approvals — FDA: no, EMA: no, PMDA: no
Description: recombinant Canarypox (CP) vaccine vCP205 via inguinal-subcutaneous injection
Study: 24558403
Drug: recombinant Canarypox
Approvals — FDA: no, EMA: no, PMDA: no
Description: recombinant Canarypox (CP) vaccine vCP205 via deltoid-intramuscular injection
Study: 24558403
Drug: recombinant Canarypox
Approvals — FDA: no, EMA: no, PMDA: no
Description: recombinant Canarypox (CP) vaccine vCP205
Study: 22683442
Drug: Immediate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate treatment (IT) group, n=11
Study: 10950002
Drug: Topical nitroglycerin
Normalized name: nitroglycerin Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical nitroglycerin 0.25% tid
Study: 6338064
Drug: Bland oil-in-water
Normalized name: Eagle Brand Medicated Oil
DrugBank: Eucalyptus oil (DB11114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bland oil-in-water lotion (placebo)
Study: 27036970
Drug: Online self-help
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Online self-help program for people with HIV and depressive symptoms, duration 6 to 10 weeks, with weekly motivational support from a coach.
Study: 22314532
Drug: GSK2248761 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2248761 30 mg QD for 7 days
Study: 22314532
Drug: GSK2248761 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2248761 100 mg QD for 7 days
Study: 22314532
Drug: GSK2248761 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2248761 200 mg QD for 7 days
Study: 22314532
Drug: GSK2248761 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2248761 400 mg QD for 7 days
Study: 22314532
Drug: GSK2248761 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2248761 800 mg QD for 7 days
Study: 22314532
Drug: GSK2248761 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2248761 (all doses)
Study: 19596459
Drug: Multifaceted nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multifaceted nutritional intervention (chocolate, homemade oral supplements), group exercise (moderate intensity), and oral care
Study: 10408812
Drug: Bupivacaine 5
Normalized name: Sure-Amp BUPivacaine 5 MG/ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 5 mg/ml
Study: 7769797
Drug: Remikiren 30
Normalized name: remikiren
DrugBank: Remikiren (DB00212)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remikiren 30 mg
Study: 7769797
Drug: Remikiren 100
Normalized name: remikiren
DrugBank: Remikiren (DB00212)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remikiren 100 mg
Study: 7769797
Drug: Remikiren 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remikiren 1,000 mg
Study: 2155645
Drug: High intensity
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High intensity chemotherapy (cisplatin 120 mg m‐2 i.v. day 1, cyclophosphamide 1,000 mg‐2 i.v. day 1, given at 21‐day intervals for six cycles)
Study: 2155645
Drug: High intensity
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High intensity chemotherapy
Study: 6107853
Drug: Sulfasalazine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfasalazine (1 g three times a day for six weeks)
Study: 6107853
Drug: 5-aminosalicylic acid
Normalized name: 5-aminosalicylic acid
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-aminosalicylic acid (0.5 g suppositories three times a day for six weeks)
Study: 6107853
Drug: Sulfapyridine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfapyridine (0.5 g three times a day for six weeks)
Study: 27859929
Drug: Diuretic‐induced isosmotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic‐induced isosmotic dehydration to lower SkBF (DEH)
Study: 27859929
Drug: Continuous saline
Normalized name: Uniphyllin Continus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous saline infusion to maintain SkBF (SAL)
Study: 20648661
Drug: Conventional dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dose of vitamin D (880 IU/day)
Study: 20648661
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of vitamin D (1600 IU/day)
Study: 11452709
Drug: BAY 12‐9566
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 12‐9566 (50 mg single oral dose)
Study: 8072252
Drug: Mechanical thrombolysis
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical thrombolysis (M) using heparinized saline as the pulsing agent
Study: 8072252
Drug: Pharmacomechanical thrombolysis
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacomechanical thrombolysis (PM) using concentrated urokinase as the pulsing agent
Study: 2522475
Drug: Ipratropium bromide,
Normalized name: Ipratropium Bromide, compounding powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipratropium bromide, 60 micrograms by metered-dose inhaler
Study: 21481716
Drug: Maltitol test
Normalized name: Maltitol
DrugBank: Maltitol (DB16867)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maltitol test drink (50 g)
Study: 21481716
Drug: Glucose test
Normalized name: GLUCOSE TEST
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose test drink (50 g)
Study: 19656102
Drug: Intracoronary administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary administration of stem cells
Study: 16917170
Drug: Intratympanic gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratympanic gentamicin instillation therapy
Study: 16917170
Drug: Normal vestibular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal vestibular evoked myogenic potentials before therapy
Study: 14972474
Drug: Perioperative antibiotics
Normalized name: ENSURE SURGERY PERIOPERATIVE KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative antibiotics (cefazolin and ciprofloxacin)
Study: 14972474
Drug: No perioperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: No perioperative antibiotics (control group)
Study: 2820298
Drug: Zinc gluconate
Normalized name: Zinc Gluconate
DrugBank: Zinc gluconate (DB11248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zinc gluconate lozenge (23 mg of elemental zinc), administered 8 times per day for 5 days (trial 1)
Study: 2820298
Drug: Zinc gluconate
Normalized name: Zinc Gluconate
DrugBank: Zinc gluconate (DB11248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zinc gluconate lozenge (23 mg of elemental zinc), administered 8 times per day for 7 days (trial 2)
Study: 2820298
Drug: Zinc gluconate
Normalized name: Zinc Gluconate
DrugBank: Zinc gluconate (DB11248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zinc gluconate lozenge (23 mg of elemental zinc)
Study: 22385074
Drug: Imiquimod 5%
Normalized name: Imiquimod 5% Topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 5% cream for 4 weeks before Mohs micrographic surgery (MMS)
Study: 22385074
Drug: Imiquimod 5%
Normalized name: Imiquimod 5% Topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 5% cream for 4 weeks before MMS
Study: 20399360
Drug: Nonoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoperative treatment (medications, physical therapy, lumbar injection)
Study: 16239154
Drug: Medication for
Normalized name: SALICYLIC ACID 10 mg in 1 mL TOPICAL LOTION [Serious Skincare Continuously Clear Acne Medication For Problematic skin Dry Lo Pro All- Over Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication for 5 weeks, followed by combined medication plus CBT for 5 weeks
Study: 16239154
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment for 5 weeks, followed by CBT alone
Study: 11940259
Drug: Emerging therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emerging therapies in critical care
Study: 9505999
Drug: Erythromycin 250
Normalized name: erythromycin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 250 mg taken orally 4 times daily
Study: 8180726
Drug: ACE-inhibitors (enalapril
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE-inhibitors (enalapril and lisinopril)
Study: 8180726
Drug: Calcium antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium antagonists (isradipine and felodipine)
Study: 8180726
Drug: Beta-blockers and/or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockers and/or diuretics
Study: 24514432
Drug: Unbalanced crystalloid
Normalized name: Crystal ammonia
DrugBank: Ammonium carbonate (DB15926)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unbalanced crystalloid (chloride: 155.5 mmol/l)
Study: 24514432
Drug: Balanced crystalloid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced crystalloid and balanced colloid (6% w/v hydroxyethyl starch 130/0.42; chloride: 98 and 112 mmol/l)
Study: 22953991
Drug: 30 mCi 131I
Normalized name: iobenguane (131I)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 30 mCi 131I plus lithium 900 mg/day for 7 days (Group B)
Study: 21106618
Drug: Integrated motivational
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated motivational interviewing and cognitive behavioural therapy plus standard care